Selective Btk Inhibitors for Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Btk inhibitors lack selectivity over Src-family kinases, leading to severe adverse effects due to their non-selective inhibition, which is prohibitive for their development and use in treating autoimmune and inflammatory diseases.
Innovation Solution
Development of Btk inhibitor compounds, specifically those according to Formula I, which are designed to selectively inhibit Btk activity with an IC50 of 10 µM or lower, thereby minimizing adverse effects associated with Src-family kinase inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Btk inhibitor compounds are used to treat autoimmune and inflammatory diseases, then therapeutic efficacy is improved, but severe adverse effects occur due to non-selective inhibition of Src-family kinases
Solution Approach 1:
The patent applies local quality by designing Btk inhibitor compounds with specific molecular structures (Formula I) that confer selective binding affinity to Btk while excluding Src-family kinases. The compounds contain specific structural features including a heterocyclic ring system, a linker, and a terminal group that together enable selective interaction with Btk's ATP binding site, thereby achieving therapeutic efficacy without off-target inhibition of Src-family kinases
Solution Approach 2:
The patent employs parameter changes by optimizing the IC50 values of the Btk inhibitor compounds to be in the nanomolar to low micromolar range, and by carefully tuning the selectivity profile through structural modifications. The compounds are designed to maintain potent Btk inhibition (IC50 ≤ 10 µM) while demonstrating >100-fold selectivity over Src-family kinases, thereby resolving the contradiction between efficacy and safety
2Adaptability or versatility
If non-selective Btk inhibitors are used, then broad kinase inhibition is achieved, but selectivity over Src-family kinases is lost leading to prohibitive adverse effects
Solution Approach 1:
The patent applies segmentation by dividing the kinase inhibition space into distinct targets: Btk is selectively inhibited while Src-family kinases are spared. The compound structure is segmented into specific pharmacophoric elements that recognize Btk's unique structural features, thereby achieving selective inhibition rather than broad non-specific kinase suppression
Solution Approach 2:
The patent uses the compound structure of Formula I as an intermediary that mediates selective interaction with Btk. The specific molecular architecture acts as a mediator that bridges the gap between the desired therapeutic effect (Btk inhibition) and the need to avoid off-target effects (Src-family kinase inhibition), enabling selective binding through complementary structural features
Data Source
AI summary
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.